VYYRF / Voyageur Pharmaceuticals completes second and final closing of its private placement for gross proceeds of $1,019,953.53

Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) told investors it has completed the formulation and engineering for production processing of its dr more_horizontal

Voyageur Pharmaceuticals said it is adding experienced finance and accounting professional Kevin R. McBeth to its board following the retirement of more_horizontal

A Calgary-based company has unveiled a new process to produce fullerenes and their derivatives, which are among the world's most valuable materials, o more_horizontal

Voyageur Pharmaceuticals has highlighted a new white paper that outlines the imaging properties of its product SmoothX and its potential to optimize a more_horizontal

Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) announced that it has successfully completed the environmental and geotechnical field work at its F more_horizontal

Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) has announced a new development and license agreement with Rain Cage Carbon Inc to develop cuttin more_horizontal

Amid supply chain challenges, demand for medical imaging contrasts such as barium sulfate and iodine which are used by radiologists to diagnose patien more_horizontal

Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) said it has completed comparative studies of its SmoothX barium contrast media versus ReadiCat 2% more_horizontal